The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst); Takeda (Inst)
 
Yu Sunakawa
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Akihito Kawazoe
No Relationships to Disclose
 
Yoshinori Kagawa
No Relationships to Disclose
 
Ken Kato
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Merck Serono; MSD Oncology; Ono Pharmaceutical; Shionogi
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tadamichi Denda
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Manabu Shiozawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
HIsato Kawakami
No Relationships to Disclose
 
Taito Esaki
Honoraria - Chugai Pharma; Eisai; Lilly Japan; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); DS Pharma Biomedical (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis/Pfizer (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Yukiko Abe
No Relationships to Disclose
 
Shogo Nomura
No Relationships to Disclose
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)